- March 20, 2019 10:01 (CET)Regulatory
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that preclinical findings support the positioning of its drug candidate T20K as a prophylactic agent for the treatment of multiple sclerosis (MS). This indicates that the substance could be used to mitigate or prevent MS episodes and potentially even delay the disease progression. Early disease intervention, such as this, is currently not targeted by other treatments available.
- February 14, 2019 08:03 (CET)Regulatory
Summary of the year-end report
- February 7, 2019 07:56 (CET)Regulatory
Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the Disciplinary Committee at Nasdaq Stockholm has decided to impose disciplinary sanctions on the company for violation of Nasdaq First North regulations. The Disciplinary Committee instructs Cyxone to pay the stock exchange a fine of SEK 200,000, corresponding to two annual fees as a result of violations regarding the rules of the regulations for disclosure of insider information during the second half of 2017.
- February 4, 2019 10:19 (CET)Regulatory
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,159,710 B2 – a divisional patent related to the already approved ‘parent patent’ for drug candidate T20K in development for the treatment of multiple sclerosis (MS).
- December 3, 2018 17:34 (CET)
Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.
- November 28, 2018 08:47 (CET)Regulatory
Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive results in the toxicology studies. The drug candidate T20K has now shown to be safe for people to ingest and the next step is to test the effect of T20K in clinical trials.
- November 21, 2018 08:46 (CET)Regulatory
Summary of the interim report
- October 31, 2018 08:25 (CET)
Cyxone (publ) announced today that the internationally renowned research house First Berlin Equity Research has published an independent analysis report of the company.
- October 23, 2018 08:25 (CEST)Regulatory
Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study. The clinical site located in Western Europe has been carefully evaluated based on a number of crucial criteria and will treat the first healthy volunteers in the T20K clinical phase 1 study developed for the treatment of multiple sclerosis (MS). This means that the company is well aligned with the planned preparations for T20K's first clinical study prior to the start of recruitment of healthy volunteers as well as completion of the remaining preclinical program.
- August 17, 2018 14:23 (CEST)Regulatory
Cyxone AB (publ) announced today that the company changes Certified Adviser.